前列腺癌放疗后患者报告尿失禁的剂量效应量化
该多中心前瞻性研究纳入298例接受IMRT的前列腺癌患者,采用ICIQ-SF问卷每6个月评估3年晚期患者报告尿失禁(LPRUI),发现EQD2(α/β=0.8Gy)>80Gy时LPRUI风险明显增加,既往腹部/盆腔手术和TURP是最显著预测因素。
要点
- EQD2>80Gy时LPRUI风险明显增加。
- 既往腹部/盆腔手术和TURP是显著预测因素。
- 基线症状是6个终点中5个的主要预测因素。
核心结论
- 前列腺癌放疗后LPRUI强烈依赖于EQD2和少数临床因素。
- 中度大分割对LPRUI风险的影响大于预期。
- 基线症状与LPRUI风险增加相关。
研究设计与样本
- 多中心研究DUE01纳入298例前列腺癌患者,前瞻性收集临床和剂量学数据。
- 患者接受常规分割(74-80Gy,1.8-2Gy/次)或中度大分割(65-75.2Gy,2.2-2.7Gy/次)IMRT,5次/周。
- LPRUI通过ICIQ-SF问卷在放疗开始/结束及每6个月评估,考虑6种3年LPRUI终点(主观和客观)。
主要发现
- 最严重终点(ICIQ-SF>12)的发生率为5.1%。
- EQD2(α/β=0.8Gy)拟合数据最佳,EQD2>80Gy时LPRUI风险明显增加。
- 既往腹部/盆腔手术和既往TURP是最显著预测LPRUI的临床因素。
- 模型拟合优度和校准良好,经bootstrap内部验证确认。
- 基线症状是6个终点中5个的主要预测因素。
关键数值与推荐
- LPRUI最严重终点定义为ICIQ-SF>12,发生率5.1%。
- EQD2计算采用α/β=0.8Gy,风险增加阈值为EQD2>80Gy。
临床怎么用
- 制定前列腺癌放疗计划时,应关注EQD2(α/β=0.8Gy)并尽量避免超过80Gy以降低LPRUI风险。
- 评估患者时应询问既往腹部/盆腔手术史和TURP史,识别LPRUI高风险患者。
- 基线ICIQ-SF症状评估有助于预测放疗后LPRUI风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Urinary incontinence following radiotherapy (RT) for prostate cancer (PCa) has a relevant impact on patient's quality of life. The aim of the study was to assess the unknown dose-effect relationship for late patient-reported urinary incontinence (LPRUI). METHODS AND MATERIALS: Patients were enrolled within the multi-centric study DUE01. Clinical and dosimetry data including the prescribed 2Gy equivalent dose (EQD2) were prospectively collected. LPRUI was evaluated through the ICIQ-SF questionnaire filled in by the patients at RT start/end and therefore every 6months. Patients were treated with conventional (74-80Gy, 1.8-2Gy/fr) or moderately hypo-fractionated RT (65-75.2Gy, 2.2-2.7Gy/fr) in 5 fractions/week with intensity-modulated radiotherapy. Six different end-points of 3-year LPRUI, including or not patient's perception (respectively, subjective and objective end-points), were considered. Multivariable logistic models were developed for each end-point. RESULTS: Data of 298 patients were analyzed. The incidence of the most severe end-point (ICIQ-SF>12) was 5.1%. EQD2 calculated with alpha-beta=0.8Gy showed the best performance in fitting data: the risk of LPRUI markedly increased for EQD2>80Gy. Previous abdominal/pelvic surgery and previous TURP were the clinical factors more significantly predictive of LPRUI. Models showed excellent performances in terms of goodness-of-fit and calibration, confirmed by bootstrap-based internal validation. When included in the analyses, baseline symptoms were a major predictor for 5 out of six end-points. CONCLUSIONS: LPRUI after RT for PCa dramatically depends on EQD2 and few clinical factors. Results are consistent with a larger than expected impact of moderate hypo-fractionation on the risk of LPRUI. As expected, baseline symptoms, as captured by ICIQ-SF, are associated to an increased risk of LPRUI.
引用
- Cozzarini C, Rancati T, Palorini F, et al. Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose-effect. Radiother Oncol. 2017. PMID: 28826629. doi:10.1016/j.radonc.2017.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。